[{"id":"a9a4b065-a72c-4e31-861d-bbef6a0e8d93","acronym":"PEOPLE","url":"https://clinicaltrials.gov/study/NCT03447678","created_at":"2021-01-18T16:59:58.507Z","updated_at":"2024-07-02T16:36:29.303Z","phase":"Phase 2","brief_title":"Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.","source_id_and_acronym":"NCT03447678 - PEOPLE","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression","tags":["EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2021-06-09"},{"id":"5c07abfd-0d75-4d99-b035-0c255176f1de","acronym":"","url":"https://clinicaltrials.gov/study/NCT00471887","created_at":"2021-03-25T14:35:46.049Z","updated_at":"2024-07-02T16:36:39.629Z","phase":"Phase 2","brief_title":"Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma","source_id_and_acronym":"NCT00471887","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF • CD8 • CD4 • FOXP3","pipe":" | ","alterations":" FOXP3 expression","tags":["BRAF • CD8 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2020-10-26"},{"id":"ee17c56b-100b-4f4d-add7-d4b4a993c0e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01842139","created_at":"2021-01-18T08:12:34.440Z","updated_at":"2024-07-02T16:37:13.134Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission","source_id_and_acronym":"NCT01842139","lead_sponsor":"University of Chicago","biomarkers":" CD8 • IFNG • WT1 • FOXP3","pipe":" | ","alterations":" FOXP3 expression","tags":["CD8 • IFNG • WT1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/05/2011","start_date":" 12/05/2011","primary_txt":" Primary completion: 02/02/2015","primary_completion_date":" 02/02/2015","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2018-03-09"},{"id":"2d54c98d-2a85-4b12-b07f-d3d93dbe593d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03446911","created_at":"2021-01-18T16:59:43.511Z","updated_at":"2024-07-02T16:37:13.467Z","phase":"Phase 1/2","brief_title":"Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery","source_id_and_acronym":"NCT03446911","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • CD4 expression • FOXP3 expression","tags":["PD-L1 • CD8 • PD-1 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • CD4 expression • FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2018-02-27"},{"id":"7cf8ad5e-81d5-4562-a67f-e90b14ee0c57","acronym":"","url":"https://clinicaltrials.gov/study/NCT01366170","created_at":"2021-01-18T05:35:45.754Z","updated_at":"2024-07-02T16:37:31.977Z","phase":"","brief_title":"Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma","source_id_and_acronym":"NCT01366170","lead_sponsor":"Children's Oncology Group","biomarkers":" ALK • CD276 • CD4 • FOXP3","pipe":" | ","alterations":" FOXP3 expression","tags":["ALK • CD276 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOXP3 expression"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-05-19"}]